Site icon pharmaceutical daily

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline of virology programs and plans for 2023 during Enanta’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. PT.

“Building upon the advancements in both our COVID-19 and RSV programs during this past year, we enter 2023 poised for success by expanding our pipeline and executing against several important milestones to pursue our goal of developing curative therapies for viral infections,” said Jay R. Luly, President & Chief Executive Officer at Enanta Pharmaceuticals. “In particular, we are encouraged that we are on track to announce data in the first half of 2023 from SPRINT, our ongoing Phase 2 study of EDP-235, an oral, 3CL protease inhibitor specifically designed for the treatment of COVID-19. We are also excited to present new preclinical in vivo data demonstrating EDP-235’s robust antiviral treatment effect and its ability to prevent the transmission of COVID-19 in a ferret model. We are also enthusiastic about expanding our COVID-19 treatment program by developing SARS-CoV-2 Papain-Like Protease (PLpro) inhibitors. We believe that having multiple mechanisms to treat COVID-19, either alone or in combination, will allow us to bring best-in-class options to market for a range of patients suffering from this debilitating and deadly virus. In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023. Additionally, we are pleased to build out our respiratory virology treatment portfolio with the addition of a new program to develop a broader spectrum antiviral that targets both hMPV and RSV with a single agent and plan to select a clinical candidate in the fourth quarter of 2023. Overall, we look to continue to leverage our expertise and previous successes in virology to deliver on our goal of providing effective treatments for respiratory infections to all vulnerable patient populations.”

During the presentation, Dr. Luly will highlight Enanta’s pipeline program updates and expectations for 2023.

Pipeline Updates

COVID-19 (SARS-CoV-2)

Respiratory Syncytial Virus (RSV)

Human Metapneumovirus (hMPV)/RSV

Hepatitis B Virus (HBV)

Webcast Information

Enanta’s presentation will take place on Tuesday, January 10, 2023 at 3:00 p.m. PT. A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 60 days.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

Forward Looking Statements

This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta’s clinical programs in RSV, SARS-CoV-2 and HBV and its preclinical program in hMPV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV, SARS-CoV-2, HBV and hMPV; the discovery and development risks of Enanta’s programs in RSV, SARS-CoV-2, HBV and hMPV; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; any continuing impact of the COVID-19 pandemic on business operations and clinical trials; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s Form 10-Q for the fiscal quarter ended June 30, 2022, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

Contacts

Media and Investor:
Jennifer Viera

617-744-3848

jviera@enanta.com

Exit mobile version